Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 4/20 | 1.00 |
| ▸ | MMP2 | P08253 | 16/20 | 0.42 |
| ▸ | MMP3 | P08254 | 12/20 | 0.42 |
| ▸ | MMP7 | P09237 | 11/20 | 0.42 |
| ▸ | MMP1 | P03956 | 11/20 | 0.41 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | FCER2 | P06734 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274076 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6813847 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6813844 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL3500092 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6942162 | 0.92 | ADAM17 (0.85) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6946003 | 0.92 | ADAM17 (0.85) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6946135 | 0.92 | ADAM17 (0.85) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6946832 | 0.92 | ADAM17 (0.85) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6942514 | 0.92 | ADAM17 (0.85) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6941769 | 0.92 | ADAM17 (0.85) | ADAM17MMP2MMP3MMP7MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274626-A1 | TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-05 | — | — | US | claimed |
| WO-2007016597-A2 | TARGETING TNF-ALPHA CONVERTING ENZYME (TACE)-DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-08 | — | — | WO | claimed |
| EP-0993442-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-04-23 | — | — | EP | claimed |
| US-6235787-B1 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; BONE DISORDERS; SKIN DISORDERS; MULTIPLE SCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-05-22 | — | — | US | claimed |
| US-20240156867-A1 | ENGINEERED IMMUNE CELL THERAPEUTICS AND METHODS OF USE | Catamaran Bio, Inc. | 2024-05-16 | — | — | US | disclosed |
| US-20090274626-A1 | TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2007016597-A2 | TARGETING TNF-ALPHA CONVERTING ENZYME (TACE)-DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20050019743-A1 | Compounds and methods for improving platelet recovery and function | CENTER FOR BLOOD RESEARCH, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004105837-A2 | COMPOUNDS AND METHODS FOR IMPROVING PLATELET RECOVERY AND FUNCTION | CENTER FOR BLOOD RESEARCH, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| EP-0993442-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6235787-B1 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; BONE DISORDERS; SKIN DISORDERS; MULTIPLE SCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-05-22 | — | — | US | disclosed |